1. Home
  2. CNXU vs UNCY Comparison

CNXU vs UNCY Comparison

Compare CNXU & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Conexeu Sciences Inc. Common Stock

CNXU

Conexeu Sciences Inc. Common Stock

BUY

Current Price

$3.10

Market Cap

92.8M

Sector

Health Care

ML Signal

BUY

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$3.88

Market Cap

109.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXU
UNCY
Founded
2022
2016
Country
United States
United States
Employees
N/A
22
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.8M
109.7M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CNXU
UNCY
Price
$3.10
$3.88
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $28.40
AVG Volume (30 Days)
329.9K
★ 945.3K
Earning Date
02-03-2027
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $675,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10,812.60
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$3.35
52 Week High
$13.66
$8.74

Technical Indicators

Market Signals
Indicator
CNXU
UNCY
Relative Strength Index (RSI) 39.85 40.26
Support Level $3.05 $3.35
Resistance Level $4.36 $5.78
Average True Range (ATR) 0.56 0.23
MACD 0.08 0.03
Stochastic Oscillator 12.06 55.63

Price Performance

Historical Comparison
CNXU
UNCY

About CNXU Conexeu Sciences Inc. Common Stock

Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Share on Social Networks: